%PDF-1.4
%
49 0 obj
<>
endobj
46 0 obj
<>
endobj
203 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-24T13:42:28Z
2024-03-29T03:50:22-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T03:50:22-07:00
application/pdf
Heather
201102.omeract
uuid:eab60219-1dd1-11b2-0a00-6208275d6100
uuid:eab6021b-1dd1-11b2-0a00-aa0000000000
endstream
endobj
35 0 obj
<>
endobj
36 0 obj
<>
endobj
50 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
18 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
21 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
235 0 obj
[240 0 R]
endobj
236 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
55 54 m
559 54 l
S
/CS0 cs 0 0 0 0 scn
/GS0 gs
103.81 56.88 407.5 -10.83 re
f*
Q
Q
q
1 0 0 1 0 2.1739 cm
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
0.5 w
103.81 56.88 407.5 -10.83 re
S
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
465 777 92 -27 re
f*
BT
0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:4)Tj
0 Tw -46.2952 -0.0313 Td
(910)Tj
/TT1 1 Tf
-0.00011 Tc 0.02499 Tw 0.4119 84.8494 Td
[(1)37 (1.)-875 (Felson DT)74 (, )55 (Anderson JJ, Boers M, et al. )55 (American College of)]TJ
0 Tc 2.1381 -1.25 Td
[(Rheumatology)65 (. Preliminary definition of improvement in)]TJ
0 -1.25 TD
[(rheumatoid arthritis. )55 (Arthritis Rheum 1995;38:727-35.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875 (van Gestel )55 (AM, Prevoo ML, van \221t Hof MA, van Rijswijk MH, van)]TJ
0 Tc 2.175 -1.25 Td
(de Putte LB, van Riel PL. Development and validation of the)Tj
-0.00011 Tc T*
[(European League )55 (Against Rheumatism response criteria for)]TJ
0 Tc T*
[(rheumatoid arthritis. Comparison with the preliminary )55 (American)]TJ
T*
[(College of Rheumatology and the )18 (W)80 (orld Health)]TJ
T*
[(Or)18 (ganization/International League )55 (Against Rheumatism Criteria.)]TJ
T*
(Arthritis Rheum 1996;39:34-40.)Tj
-2.175 -1.25 Td
[(13.)-875 (Strand )18 (V)129 (, Cohen S, Schif)18 (f M, et al. )18 (T)35 (reatment of active rheumatoid)]TJ
2.175 -1.25 Td
(arthritis with leflunomide compared with placebo and methotrexate.)Tj
-0.00011 Tc T*
[(Leflunomide Rheumatoid )55 (Arthritis Investigators Group. )55 (Arch Intern)]TJ
0 Tc T*
(Med 1999;159:2542-50.)Tj
-2.175 -1.25 Td
[(14.)-875 (Bankhurst )55 (AD. Etanercept and methotrexate combination therapy)65 (.)]TJ
2.175 -1.25 Td
(Clin Exp Rheumatol 1999;17:S69-72.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875 (T)70 (aylor )18 (WJ, Rajapakse CN, Harris KA, Harrison )55 (AA, Corkill MM.)]TJ
0 Tc 2.175 -1.25 Td
(Inpatient treatment of rheumatoid arthritis with synacthen depot: a)Tj
T*
(double blind placebo controlled trial with 6 month followup. )Tj
T*
(J Rheumatol 1999;26:2544-50.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875 (Anderson JJ, )18 (W)80 (ells G, )18 (V)111 (erhoeven )55 (AC, Felson DT)74 (. Factors)]TJ
0 Tc 2.175 -1.25 Td
(predicting response to treatment in rheumatoid arthritis: the)Tj
T*
[(importance of disease duration. )55 (Arthritis Rheum 2000;43:22-9.)]TJ
-2.175 -1.25 Td
[(17.)-875 (Rojkovich B, Hodinka L, Balint G, et al. Cyclosporin and)]TJ
2.175 -1.25 Td
(sulfasalazine combination in the treatment of early rheumatoid)Tj
T*
(arthritis. Scand J Rheumatol 1999;28:216-21.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875 (Felson DT)74 (, LaV)111 (alley MP)111 (, Baldassare )55 (AR, et al. )18 (The prosorba)]TJ
2.175 -1.25 Td
(column for treatment of refractory rheumatoid arthritis: a)Tj
0 Tc T*
[(randomized, double-blind, sham-controlled trial. )55 (Arthritis Rheum)]TJ
0 Tw T*
(1999;42:2153-9.)Tj
0.02499 Tw -2.175 -1.25 Td
[(19.)-875 (Lassere M, Boers M, van der Heijde D, et al. Smallest detectable)]TJ
2.175 -1.25 Td
[(dif)18 (ference in radiological progression. J Rheumatol 1999;26:731-9.)]TJ
30.825 38.75 Td
[(20.)-875 (Zweig MH, Campbell G. Receiver)20 (-operating characteristic \(ROC\))]TJ
2.175 -1.25 Td
(plots: a fundamental evaluation tool in clinical medicine. Clin)Tj
T*
(Chem 1993;39:561-77.)Tj
-2.175 -1.25 Td
[(21.)-875 (van der Heijde D, Boonen )55 (A, Boers M, Kostense P)111 (, van der Linden)]TJ
2.175 -1.25 Td
[(S. Reading radiographs in chronological order)40 (, in pairs or as single)]TJ
T*
(films has important implications for the discriminative power of)Tj
T*
(rheumatoid arthritis clinical trials. Rheumatology 1999;38:1213-20.)Tj
-2.175 -1.25 Td
[(22.)-875 (van der Heijde D, Dankert )18 (T)74 (, Nieman F)80 (, Rau R, Boers M.)]TJ
2.175 -1.25 Td
(Reliability and sensitivity to change of a simplification of the)Tj
T*
(Sharp/van der Heijde radiological assessment in rheumatoid)Tj
T*
(arthritis. Rheumatology 1999;38:941-7.)Tj
-2.175 -1.25 Td
[(23.)-875 (Kuper IH, van Leeuwen MA, van Riel PL, et al. Influence of a)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(ceiling ef)18 (fect on the assessment of radiographic progression in)]TJ
0 Tc T*
(rheumatoid arthritis during the first 6 years of disease. J Rheumatol)Tj
0 Tw T*
(1999;26:268-76.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875 (Molenaar ET)74 (, Edmonds J, Boers M, van der Heijde DM, Lassere)]TJ
0 Tc 2.175 -1.25 Td
[(M. )55 (A)-220 (practical exercise in reading RA)-220 (radiographs by the Larsen)]TJ
T*
(and Sharp methods. J Rheumatol 1999;26:746-8.)Tj
-2.175 -1.25 Td
[(25.)-875 (Cohen J. )55 (A)-220 (coef)18 (ficient agreement for nominal scales. Educ Psychol)]TJ
2.175 -1.25 Td
(Meas 1960;20:37-46.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(26.)-875 (Altman DG. Practical statistics for medical research. London:)]TJ
0 Tc 2.175 -1.25 Td
(Chapman & Hall; 1991.)Tj
-2.175 -1.25 Td
[(27.)-875 (Cicchetti DV)129 (, Feinstein )55 (AR. High agreement but low kappa: II.)]TJ
2.175 -1.25 Td
(Resolving the paradoxes. J Clin Epidemiol 1990;43:551-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(28.)-875 (Samsa GP)111 (. Sampling distributions of p\(pos\) and p\(neg\). J Clin)]TJ
0 Tc 2.175 -1.25 Td
(Epidemiol 1996;49:917-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875 (Bland JM, )55 (Altman DG. Statistical methods for assessing agreement)]TJ
0 Tc 2.175 -1.25 Td
(between two methods of clinical measurement. Lancet 1986;)Tj
0 Tw T*
(1:307-10.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(30.)-875 (Bland JM, )55 (Altman DG. Measurement error)55 (. BMJ 1996;313:744.)]TJ
T*
[(31.)-875 (Shrout P)111 (, Fleis J. Intraclass correlations: use in assessing rater)]TJ
0 Tc 2.175 -1.25 Td
[(reliability)65 (. Psychol Bull 1979;86:420-8.)]TJ
ET
q
/GS0 gs
1.25 TL /Fm0 Do
Q
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
28 0 obj
<>stream
H$1
0_pX'v 4) aL
%8?XrfٙoIa0ȷGP;o-H:#WF?{Kl|ILyrj"}im L
endstream
endobj
27 0 obj
<1.3<>>>
endobj
25 0 obj
<>/ExtGState<>/ProcSet[/PDF/ImageB]/XObject<>>>
endobj
24 0 obj
<>/Filter/CCITTFaxDecode/Height 568/ImageMask true/Length 4479/Subtype/Image/Type/XObject/Width 904>>stream
LտI4}\L$8kE/Gخkc}|.`~wkz#p&i
q#ZD)xF*^
g쫻'GU7sE4>]<_193a|mJcߗH}
0B&GtECGHhN7pzqƭ/z"Br
'"e#AaE<6o/t߾~+V/*HO_}G
AT_aڦXص X,6a;
3epAANaٞRgzC"82Rxl~T*CM픈J}y4h]oG˲2>G0v_#|v_/Yp[rnx-9ܸ)REFJTQ '.Z)I"E> ]"xoER\UGPZҪ+㤝RRIJ?ZTmQUZ%PT*qK=I `X^AW&h,+R-:N>{/ݮd~E:
$ȳC˦m
0jXcTaEu0#Ä{cӤ}z#LoTh4Rj2쏑;#|]QNS W [#nKJ)U*CIukJ+)iub)eAiXQhfyʂ=9PXL`# ϨA2>5}0Nr=dQ`]_]A0,<~}Z@7WW0/ZTwPW" --\DYT[ $=TUҿ#Ȓ3E;T$@%|량c5"
Dq"vn5ƈg\gu!y숧FL#m=m$F|-;]hAH
{>qQ)̟#|Frj_7ˣ1`])G|]~c#\F2Ge/"mx.Ngy/c uA3M/;\\\i;_VkvFt_GKkc]4":餈FplWPd~8d}i:t4PL6˪xiuDu5im0hPM!
Xvj(pa+ذDC E$"40T^;KGbJQ9hE-ΌCP+_%mB ֡u-9YP">Gͣ!tF%Fь|q?
q=Iiqzm}ZIhBIq#F4ʃQIT'h~UR/Lѯ$&s^B#TƑ~?I6( I2<&xF>P[ۯ-i/oi⟪%i/R~Q[waq<^2 .օRn4e]5dW*IґuTZ?xN::+SDUYR T&TITM@UABG#3:#h]
?8фGKtG>GF08f?@Qt
Ac4D~*B}?뾕jz.'8xJ8DtCQ
%GuKX.FP`aj#
*;3u*#5TF2Q%@* F~@Zim]!%?Jz_J#qtކ_ t+@"O8릗mRjn-uU7H^ҿ<K]{S3 ם*{k訆dV_Kv>V6VIW{#ތ*1jVmU6uG쎢o,u_kUa0GZFV5B"IS AS kSIi.+ROA=cŕ'8-UTIŸud###bePu>/B/t-In/^)
:"mhEL HIƨ~Ss2P*A?JW믯MUyHѷb"C]$#m>G@qGE[<A#؋Z֡QXc8[L/P߷_U+'T^ݯ]}V0KmI-GH1m$D\Aq*A+Z^C/h4dXO&o9UUAKUUQO_D:#ցIUHkW#T /] A:Tv'(vQU;,ֵ7h_/|EWM @tE׆W(rcUֽZzGTQe8"ZȨ\h./IzB]!H{OK#.B2?U^iV4j(T|/F;Dw6kWwᠡ>'e<g*?'GPGn)ZM8aipՊM8:];Mڵd}>5aö5a m-dtƱMPi?}:M;6oMRmD#+$غ+#`n" @
endstream
endobj
67 0 obj
<>
endobj
52 0 obj
[/ICCBased 69 0 R]
endobj
69 0 obj
<>stream
H앉_ǟESIBtJd))v%Ii9E#rN{N("$4$&4ݐ62u6 ]<'f̌l>w@Vr@X?~J;?tƃ
H", !!p~]9)Zk?YZ3\e}AJ לkKHr@2ל
~|x~[ #yƵ6?0ll6ocllĶdD#ٶ!<Xk#x=/),7?\l1v-r6$JiI5I[0h\Ll5tJ*g~u={v̸PsѶEW_..vfQw[Ы;]}'N.J_/e_w7ަ?]LUL\OAbD1aR %֒|lϸq28r宏?$Rb*p+%O>^I*J*,q&b9jZ4iϧk7=د4r43"jg|5P\9sӜwe~u:^9J~
_oalbtq&&uK6MoWXHZ4ZYX=.[kjӽLVsEJw)vBujwXʸvx~5kgj.Xcʯۿ'
z70gƖMsxZkF(ED>ojv%!1im;v
^K$5tڧys$#C:L5+7z_oDT/pBxsIǑ%e>+ﭰ?yUgktkkꖜ8|AކM+-sZͮ{wnsw̝~}#'kּ;ő7oS>s?@ω/+T6z*5QIT$-o>%A@+<2N 5QDo&2\d